Amgen Inc. (AMGN)

AMGN beats first-quarter estimates for earnings and sales. Sales of most of its products, Prolia, Xgeva, Repatha, Blincyto and Evenity beat estimates.

In today's unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially those...

Amgen Inc. (NASDAQ:AMGN ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Justin Claeys - VP, IR Robert Bradway - Chairman, CEO & President Murdo Gordon - EVP, Global Comm...

While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to ...

Amgen (AMGN) came out with quarterly earnings of $4.90 per share, beating the Zacks Consensus Estimate of $4.16 per share. This compares to earnings of $3.96 per share a year ago.

Amgen on Thursday said its first-quarter profit rose 24%, handily exceeding Wall Street expectations, as product sales increased 11% and profit margins widened.

While the strategy involves buying the Dogs of the Dow at the start of January, there are a few still worth betting on as markets regain lost ground.

Reliable dividend income from high-quality companies is a great option for investors seeking to ride out stock market turbulence. Biotech giant Amgen (AMGN 0.82%) exemplifies this strategy with its 3....

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.